GlassScriptPhysician profile
Sarah Khan
NPI 1235663071
$1,873.62
in general payments reported to CMS, 2019-2025
23 companies · $104 in 2025
The $104 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.72 · 2022: $221 · 2023: $533 · 2024: $998 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.63 |
| Education | $372.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.13 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $355.05 | 2022-2025 | Jakafi |
| Janssen Biotech, INC. | $153.49 | 2023-2024 | Balversa, Akeega, Erleada |
| Merck Sharp & Dohme LLC | $121.94 | 2024 | Keytruda |
| Daiichi Sankyo INC. | $119.98 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $98.43 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $75.59 | 2022-2024 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $62.67 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $59.95 | 2023 | |
| Celgene Corporation | $55.51 | 2022-2025 | Pomalyst, Reblozyl |
| Pfizer INC. | $44.82 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $43.13 | 2024 | |
| Seagen INC. | $40.03 | 2022-2023 | Tukysa |
| Amgen INC. | $39.54 | 2023-2024 | Prolia, Evenity, Lumakras |
| Alexion Pharmaceuticals, INC. | $31.92 | 2024 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $27.36 | 2024 | |
| Glaxosmithkline, LLC. | $21.70 | 2022 | |
| Fresenius Kabi USA, LLC | $20.84 | 2025 | Stimufend |
| Genentech USA, INC. | $19.32 | 2024 | Itovebi, Tecentriq Hybreza |
| Adc Therapeutics America, INC. | $18.80 | 2023 | |
| Abbvie INC. | $17.97 | 2024 | |
| Allergan, INC. | $17.72 | 2020 | |
| Mirati Therapeutics, INC. | $15.73 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.